These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37446393)

  • 1. Cathepsin B Is Not an Intrinsic Factor Related to Asparaginase Resistance of the Acute Lymphoblastic Leukemia REH Cell Line.
    Costa IM; Effer B; Costa-Silva TA; Chen C; Ciccone MF; Pessoa A; Dos Santos CO; Monteiro G
    Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug L-asparaginase.
    Patel N; Krishnan S; Offman MN; Krol M; Moss CX; Leighton C; van Delft FW; Holland M; Liu J; Alexander S; Dempsey C; Ariffin H; Essink M; Eden TO; Watts C; Bates PA; Saha V
    J Clin Invest; 2009 Jul; 119(7):1964-73. PubMed ID: 19509471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of lysosomal protease sensitivity in the immunogenicity of the antitumor biopharmaceutical asparaginase.
    Rodrigues MAD; Pimenta MV; Costa IM; Zenatti PP; Migita NA; Yunes JA; Rangel-Yagui CO; de Sá MM; Pessoa A; Costa-Silva TA; Toyama MH; Breyer CA; de Oliveira MA; Santiago VF; Palmisano G; Barbosa CMV; Hebeda CB; Farsky SHP; Monteiro G
    Biochem Pharmacol; 2020 Dec; 182():114230. PubMed ID: 32979352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel site-specific PEGylated L-asparaginase.
    Meneguetti GP; Santos JHPM; Obreque KMT; Barbosa CMV; Monteiro G; Farsky SHP; Marim de Oliveira A; Angeli CB; Palmisano G; Ventura SPM; Pessoa-Junior A; de Oliveira Rangel-Yagui C
    PLoS One; 2019; 14(2):e0211951. PubMed ID: 30753228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell lines.
    Su N; Pan YX; Zhou M; Harvey RC; Hunger SP; Kilberg MS
    Pediatr Blood Cancer; 2008 Feb; 50(2):274-9. PubMed ID: 17514734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase.
    Asselin BL; Ryan D; Frantz CN; Bernal SD; Leavitt P; Sallan SE; Cohen HJ
    Cancer Res; 1989 Aug; 49(15):4363-8. PubMed ID: 2743326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insight into the mechanism of asparaginase-induced depletion of antithrombin III in treatment of childhood acute lymphoblastic leukemia.
    Bushman JE; Palmieri D; Whinna HC; Church FC
    Leuk Res; 2000 Jul; 24(7):559-65. PubMed ID: 10867129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway.
    Butler M; van Ingen Schenau DS; Yu J; Jenni S; Dobay MP; Hagelaar R; Vervoort BMT; Tee TM; Hoff FW; Meijerink JP; Kornblau SM; Bornhauser B; Bourquin JP; Kuiper RP; van der Meer LT; van Leeuwen FN
    Blood; 2021 Dec; 138(23):2383-2395. PubMed ID: 34280258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asparaginase pharmacology: challenges still to be faced.
    Lanvers-Kaminsky C
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):439-450. PubMed ID: 28197753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
    Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
    Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. L-Asparagine depletion levels and L-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment.
    Tsurusawa M; Chin M; Iwai A; Nomura K; Maeba H; Taga T; Higa T; Kuno T; Hori T; Muto A; Yamagata M;
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):204-8. PubMed ID: 14634792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941).
    Jarrar M; Gaynon PS; Periclou AP; Fu C; Harris RE; Stram D; Altman A; Bostrom B; Breneman J; Steele D; Trigg M; Zipf T; Avramis VI
    Pediatr Blood Cancer; 2006 Aug; 47(2):141-6. PubMed ID: 16425271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigating the gut microbial community and genes in children with differing levels of change in serum asparaginase activity during pegaspargase treatment for acute lymphoblastic leukemia.
    Dunn KA; Connors J; Bielawski JP; Nearing JT; Langille MGI; Van Limbergen J; Fernandez CV; MacDonald T; Kulkarni K
    Leuk Lymphoma; 2021 Apr; 62(4):927-936. PubMed ID: 33258724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glutaminase Activity of L-Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia.
    Chan WK; Horvath TD; Tan L; Link T; Harutyunyan KG; Pontikos MA; Anishkin A; Du D; Martin LA; Yin E; Rempe SB; Sukharev S; Konopleva M; Weinstein JN; Lorenzi PL
    Mol Cancer Ther; 2019 Sep; 18(9):1587-1592. PubMed ID: 31209181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asparaginase activities during intensified treatment with pegylated
    Lanvers-Kaminsky C; Niemann A; Eveslage M; Beck J; Köhnke T; Martin S; de Wit M; Spriewald B; Hauspurg H; Hoelzer D; Boos J; Gökbuget N
    Leuk Lymphoma; 2020 Jan; 61(1):138-145. PubMed ID: 31480965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clinically attainable dose of L-asparaginase targets glutamine addiction in lymphoid cell lines.
    Sugimoto K; Suzuki HI; Fujimura T; Ono A; Kaga N; Isobe Y; Sasaki M; Taka H; Miyazono K; Komatsu N
    Cancer Sci; 2015 Nov; 106(11):1534-43. PubMed ID: 26331698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.
    Salzer WL; Asselin BL; Plourde PV; Corn T; Hunger SP
    Ann N Y Acad Sci; 2014 Nov; 1329():81-92. PubMed ID: 25098829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced anti-cancer effect using MMP-responsive L-asparaginase fused with cell-penetrating 30Kc19 protein.
    Ryu J; Yang SJ; Son B; Lee H; Lee J; Joo J; Park HH; Park TH
    Artif Cells Nanomed Biotechnol; 2022 Dec; 50(1):278-285. PubMed ID: 36191335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective, real-time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma in Belgium.
    Mondelaers V; Ferster A; Uyttebroeck A; Brichard B; van der Werff Ten Bosch J; Norga K; Francotte N; Piette C; Vandemeulebroecke K; Verbeke C; Schmidt S; Benoit Y; Lammens T; De Moerloose B
    Br J Haematol; 2020 Jul; 190(1):105-114. PubMed ID: 32057100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A protease-resistant Escherichia coli asparaginase with outstanding stability and enhanced anti-leukaemic activity in vitro.
    Maggi M; Mittelman SD; Parmentier JH; Colombo G; Meli M; Whitmire JM; Merrell DS; Whitelegge J; Scotti C
    Sci Rep; 2017 Nov; 7(1):14479. PubMed ID: 29101342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.